Dr Reddy's semaglutide moves to two new brands after the Obeda pen recall in India

Dr Reddy's semaglutide business in India has a new face after its first injection was pulled from the market in July. The drugmaker now sells two newer brands, Obeda Pro and Obeda Plus, made by a different contract manufacturer, Reuters reported on October 23. Distributors expect the original Obeda pen to be dropped. The company denies that one product was launched to replace the other, but buyers who started on the first pen have already had to change course.

What happened to the original Obeda pen

Dr Reddy's launched Obeda in March, soon after the semaglutide patent expired in India and a crowd of domestic firms rushed to sell cheaper copies of Novo Nordisk's Ozempic. In February, Reuters had reported that the company planned to sell about 12 million injectable pens in the first year and to price them as much as 60% below the brand. That plan ran into trouble within months. Supplies of the injection stopped in July after the company found an impurity in the active ingredient, according to Reuters, and a notice it reviewed said the pens were recalled for technical evaluation. Dr Reddy's did not answer when asked whether the recall was linked to the impurity. Its oral tablet, sold under the same brand name, was not part of the recall.

At the time of the halt, the company said the injections would not be available again until November. Analysts warned then that a long gap could cost it ground in a market where rivals were launching quickly. One distributor described the recall in plain terms. "The company said there were some technical issues with Obeda injectable, and they recalled stocks from us. They said they would instead supply Obeda Pro," the distributor told Reuters, speaking anonymously because they were not cleared to talk to the press. For pharmacies, a recall means pulling boxes from shelves, sending them back up the chain and telling patients that the product they started on is gone. For patients, it means a new prescription or a different brand, and possibly a different price, at short notice.

Two new brands from a different plant

The newer products are made by Hetero Labs, while packaging for the original pen named OneSource Specialty Pharma as the manufacturer, according to materials reviewed by Reuters. Invoices showed Obeda Pro and Obeda Plus reaching the market in late July, the same month the first injection was halted. Like Ozempic and Wegovy, the two brands come in several strengths. Several distributors said they expect Dr Reddy's to stop supplying the original Obeda and to focus on the newer pair. Neither Hetero nor OneSource replied to requests for comment. That leaves an open question for anyone tracking where these pens are filled, which is the same question that has shaped supply of the branded drugs, as Novo's purchase of three Catalent fill plants showed last year.

In February, Reuters had reported that the company planned to sell about 12 million injectable pens in the first year and to price them as much as 60% below the brand.

Dr Reddy's rejected the idea of a hurried swap. The company told Reuters that work on developing and launching Obeda Pro and Obeda Plus started well before the July disruption. "The presence of multiple semaglutide brands and manufacturing arrangements reflects the breadth of our portfolio strategy and should not be interpreted as evidence that one product was launched to replace another," it said. Both accounts can be partly true. A company can plan several brands in advance and still lean on them harder when one line stops. What matters at the counter is simpler: which pen is in stock, who made it, and whether a patient's doctor and pharmacist know it is a different product from the one first prescribed. The shares closed 1.4% lower on Friday after falling as much as 2% during the session.

Why the switch matters for buyers in India

The recall came after a fast start for Dr Reddy's semaglutide sales in a crowded market. Research firm Pharmarack counted about 442,000 units of generic semaglutide sold by the company in India through September, against roughly 151,000 for Sun Pharma, the country's largest drugmaker. Pharmarack also estimated in March that India's semaglutide market would grow to 80 billion rupees by 2030, a forecast rather than a measured figure. The figures do not split sales by brand. For patients, the lesson is that a generic Ozempic in India is not a single product. Different brands from the same company can come from different factories, and a familiar company name on the box does not tell a buyer which plant filled it.

Price competition is the reason the market grew so fast, and it is also why supply gaps hurt. When a cheap generic disappears, some patients return to a costlier brand, some switch to a rival generic and some stop treatment. Others may turn to unregulated online copies, which carry the counterfeit and quality risks that pushed regulators elsewhere to act, as in Australia's decision to end compounded GLP 1 copies. Readers in India should get semaglutide only on a prescription and from a licensed pharmacy, and should check with their pharmacist if the brand or maker on the box changes. A switch between brands is a clinical decision as much as a shopping one, so it belongs in a conversation with the prescriber, not a quick swap at the counter.

What is still unanswered

Several basic facts about the Dr Reddy's semaglutide pens remain unconfirmed. Dr Reddy's did not say whether it has fixed the impurity in the active ingredient, and it did not say whether the original Obeda pen will return in November as it promised in July or be retired, as distributors expect. It has not published how many pens were recalled or how long the recalled batches were on sale. The company also did not explain how patients who started on the original pen are being moved to the new brands, or whether their prices differ. Reuters did not report prices for Obeda Pro or Obeda Plus, and we found no official price list to check. Until the company answers those questions, pharmacies are working from distributor accounts rather than from a public statement.

Regulators in India have not commented publicly on the recall in any source we could find, and Reuters did not report any safety alert tied to it. That absence matters for patients who want to know whether pens already used were affected. The full account of the halt and the new brands is in the Reuters report carried by CNBC TV18, which remains the main public source. For readers outside India, the case is a reminder that generic semaglutide supply depends on a small number of contract plants and active ingredient makers. One quality problem at one supplier can empty shelves for months, even when the product is approved and the demand is plain.

Conclusion

Dr Reddy's semaglutide supply in India now rests on Obeda Pro and Obeda Plus from Hetero Labs, after the first pen was recalled in July over an ingredient problem. The company says the new brands were planned in advance. Patients and pharmacies should confirm which product they are getting, and watch for word on whether the original pen returns.